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We wish to comment on two observations. The first concerns the authors' assessment of methodical validity of each included trial. The authors stated that this was done independently by two reviewers using a pre-determined scoring system consisting of eight criteria. It was also described that for each trial included, any disagreement not resolved by consensus was referred to a third reviewer for resolution. There are only two authors with no additional reviewer acknowledged in the paper. One can assume therefore that the authors constituted the panel of reviewers. For two to reach independent agreement on 26 scores spread over eight criteria, for each of 17 studies is a daunting task. How did the authors measure consensus on their disagreement? Did they assess each trial based on Kappa's inter-rater measurement of agreement (Landis and Koch, 1977) , or was this based on a minimum cut-off point of total score or percentage of maximum score?
Our second observation is that the authors did not sufficiently emphasize the clinical bottom line, which is of interest to clinicians and their patients. The authors used two statistical parameters to compare the clinical pregnancy rates; the odds ratio (OR), a useful statistical tool in systematic reviews for data combination and construction of meta-analysis trees; and the risk difference (or absolute risk reduction -ARR) which on inversion can be converted to the number needed to treat (NNT). The clinical bottom line therefore, from overall meta-analysis in Daya and Gunby's review is that 27 (NNT ϭ -27; 95% confidence intervals, -261 to -14) (Ola and Hammadieh, 1999 ) patients need to be treated with rFSH to produce one additional pregnancy over that from use of uFSH.
Highly purified urinary FSH (e.g. Metrodin HP; Serono, Welwyn, UK) also lacks LH activity and protein contaminants and is considerably cheaper than recombinant FSH (e.g. Gonal F; Serono). The average costs respectively are £614 versus £866 for a typical treatment cycle (comprising 225 IU of FSH daily for 11 days). A simple cost-effectiveness analysis therefore approximates to an additional cost of £6789 to achieve one extra pregnancy. However, a cost-benefit equation (i.e. total cost per absolute, rather than incremental number of pregnancies) would confer an apparent advantage to recombinant FSH.
Recombinant versus urinary FSH for ovarian stimulation in assisted reproduction
Bolarinde were not indicated in our paper) ranged from 0.9 to 1.0. In Difference 252.00 5.2 -966
those instances in which we disagreed, resolution was easily achieved by reviewing the relevant papers and discussing the respective issues to reach a consensus. Consequently, there was no need to seek arbitration from a third reviewer. The The cost-effectiveness analysis presented by Ola et al. is total validity score for each trial was calculated, as indicated incomplete because it addresses only the cost of the drugs and in our paper, as the sum of the scores of each validity criterion.
not the savings that would be accrued from the cost of cycles Regarding the second concern about the 'clinical bottom avoided owing to the higher pregnancy rate with rFSH. If one line', we are somewhat surprised with the authors' method of were to assume that a 'typical treatment cycle required 225 IU reporting the estimates of treatment effect and their costof FSH daily for 11 days' then, using the authors' figures, the effectiveness analysis. We calculated the risk difference as a cost difference between rFSH (i.e. follitropin alpha) and uFSH weighted (for sample size) mean difference in pregnancy rates is £866.00 -614.00 ϭ £252, which is the cost incurred by between recombinant follicle stimulating hormone (rFSH), each patient to obtain an improvement in pregnancy of 5.2%. representing the experimental group, and urinary FSH (uFSH),
In actual fact, the cost difference would be much smaller representing the control group. The risk difference was in because we have observed, in a meta-analysis of the secondary favour of rFSH, with an increase in the clinical pregnancy rate outcomes, a significant reduction in the total amount of rFSH of 5.2% when follitropin alpha (Gonal F; Ares Serono, Geneva, used compared with uFSH. Assuming that the non-drug-related Switzerland) was compared with uFSH in cycles of IVF, and cost for one cycle of IVF is £2000, then the cost per pregnancy 3.7% when follitropin beta (Puregon or Follistin; Organon, can be calculated as shown in Table I . Oss, The Netherlands) was compared with uFSH (the latter It is clear from this analysis that the cost per pregnancy is was not statistically significant). The authors' use of the term higher when uFSH is used compared with rFSH (follitropin absolute risk reduction (ARR) (and the related term relative alpha). Furthermore, using the event rates and drug costs as risk reduction) obtained from the computer programme they shown in the table, the cost per pregnancy would become identical only if the non-drug-related costs per cycle were as used to develop a critically appraised topic on this subject low as £600. Based on the cost of IVF treatment in Canadian (Ola and Hammadieh, 1999 ) is unfortunate because it conveys centres, this scenario is highly unlikely. Therefore, we submit the impression that rFSH reduces the 'risk' (or event rate i.e.
that the clinical bottom line is that rFSH is more efficacious pregnancy rate) compared with uFSH [and the corresponding than uFSH and, in IVF, the use of follitropin alpha is more number needed to treat (NNT) has a negative value]. Clearly, cost-effective than uFSH. a reduction in risk was not the finding in our study. The more appropriate term is the absolute treatment effect (ATE) or absolute benefit increase. Although, numerically in References this instance, ATE and ARR are the same, it is important to The NNT (of 27), to which the authors refer, was not and Gunby J. http://www.thenhs.com/bham-womens/cats provided in our paper but was calculated by them using the whole data set we published. We wish to point out that the S.Daya and J.Gunby NNT varies depending on which subgroup is analysed. Also, Department of Obstetrics and Gynecology, when the difference between two treatments is not statistically
McMaster University, HSC:3N52, significant, the confidence interval for the NNT is difficult to 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada describe. Our subgroup analyses indicated that, although the overall result was statistically significant, it was in large part because of the difference between follitropin alpha and uFSH in IVF. In this group, the risk difference was 5.2%, giving an NNT of 19 (95% confidence interval 10 to 50). The other subgroup analyses produced risk differences that were smaller and not statistically significant. Consequently, the conclusion should be that for every 19 women treated with follitropin alpha, one additional pregnancy will be achieved compared to (treating the same 19 women with) uFSH.
